In a significant development for Canadian healthcare, Apotex Health Corp. has emerged as the sole manufacturer of generic Ozempic following a manufacturing glitch at an Indian facility that has temporarily sidelined two key competitors. This situation leaves Apotex as the only source of the generic version of semaglutide, a drug that has seen skyrocketing demand and was the top-selling medication in Canada last year, generating sales of $2.9 billion.
Manufacturing Issues Create Market Vacuum
Ozempic, produced by Danish pharmaceutical giant Novo Nordisk, is primarily prescribed for individuals with type 2 diabetes. Its higher-dose counterpart, Wegovy, is marketed for weight management. With over a million Canadians using semaglutide last year, the drug’s impact is substantial. The approval of generic semaglutide began in January 2023 after Novo Nordisk’s market exclusivity expired, with Health Canada granting its first approvals in late April.
However, the landscape changed dramatically when Dr. Reddy’s Laboratories, one of the approved generic manufacturers, reported manufacturing problems at its upgraded facility. During a conference call on July 9, CEO Erez Israeli disclosed that impurities found in the pharmaceutical ingredients were “out of specifications”. He indicated that rectifying these issues could extend into late October or early November, introducing the possibility of further delays.
Apotex Steps Up Amidst Competitor Challenges
With Dr. Reddy’s production on hold, and Aspen Pharmacare also affected as it relies on Dr. Reddy’s supply, Apotex is now the only company able to fill the gap in the market. Catherine Thomas, Apotex’s vice-president of global communications, remarked, “While we didn’t anticipate being the only generic available, we continue to work with our partners to increase our supply as we understand there remains a very strong demand, particularly as the product is now available at a fraction of the cost it was previously.”
The key ingredients for Apotex’s semaglutide are sourced from India in collaboration with Orbicular Pharmaceutical Technologies. David Martin, managing director at Bloom Burton Securities Inc., views this as a positive turn for Apotex, projecting its sales of semaglutide could reach $124.4 million by the end of the fiscal year in March 2027—a figure that was based on a more competitive market.
Price Comparisons and Market Implications
The limited availability of generic options may inadvertently benefit the brand-name drug, Ozempic. In Canada, the price for the brand version stands at approximately £183 for a four-week supply, while Apotex’s generic offering is priced at £58. Although these figures do not account for potential pharmacy markups or manufacturer discounts, they illustrate the significant savings that generics can offer.
Novo Nordisk has introduced discount cards for patients outside Quebec, allowing them to access Ozempic at generic prices, although it remains unclear how this will affect the number of patients opting for the brand name. Kate Hanna, director of communications at Novo Nordisk Canada, stated that the company maintains a stable supply of Ozempic for the Canadian market.
Supply Chain Stability Remains
Despite the upheaval in the generic semaglutide market, pharmacies have reported no major disruptions in the supply of semaglutide. Youmna Rab, retail communications manager at Loblaw Companies Ltd., confirmed that they are receiving an adequate supply to meet patient needs. However, not all patients are experiencing the same access; Tom Elliott, medical director of BCDiabetes in Vancouver, noted that many patients still rely on the brand-name version, citing limited availability of generics.
Why it Matters
The emergence of Apotex as the sole supplier of generic Ozempic underscores the complexities of the pharmaceutical landscape in Canada and highlights the critical need for robust manufacturing processes. With the stakes high for millions of Canadians relying on this essential medication, the current scenario raises questions about supply chain resilience and the broader implications for drug pricing and accessibility. The temporary market monopoly held by Apotex could lead to increased scrutiny regarding pricing strategies, and patients will be watching closely as the situation develops.